AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-10. (Canceled)

11. (Previously presented) The haemostatic composition according to claim 106, wherein the ratio between the water absorbed by the haemostatic sponge according to claim 106 and the water absorbed by a conventional absorbable gelatin sponge is at the most 0.95.

12-13. (canceled)

- 14. (Previously presented) The haemostatic composition according to claim 103, wherein said composition is in the form of a haemostatic sponge, wherein at least one of the surfaces of the haemostatic sponge is covered by a top sheet.
- 15. (Previously presented) The haemostatic composition according to claim 14, wherein the top sheet is removable.
- 16. (Canceled)
- 17. (Previously presented) The haemostatic composition according to claim 103, wherein said composition is dry.
- 18. (Previously presented) A haemostatic paste prepared by pre-wetting the haemostatic composition according to claim 103 with a liquid to create a paste, wherein a haemostatic composition is in the form of a powder or flakes.

19-22. (canceled)

<u>USSN 10/562,831</u> Docket: 13323-105005

- 23. (Withdrawn/Currently amended) A method for producing a cross-linked and sterile haemostatic composition according to claim 103 comprising the steps of:
- i) mixing gelatine and hyaluronic acid or a hyaluronate salt derivative thereof, and a solvent, and
- ii) treating the mixture obtained in step i) with dry heat at a temperature between 110-200°C.
- 24. (Withdrawn) The method according to claim 23, wherein said method comprises a further step of drying the mixture obtained in step i) before treating the mixture with dry heat at a temperature between 110-200°C according to step ii).

25-26. (canceled)

- 27. (Withdrawn / Currently amended) A method for preparing the haemostatic composition according to claim 17, said method comprising the steps of:
- i) mixing gelatin, hyaluronic acid (HA) or a hyaluronate salt derivative thereof, and a solvent;
 - ii) cross-linking said composition with dry heat at 110-200°C; and
 - iii) drying said mixture.
- 28. (Canceled)
- 29. (Withdrawn / Currently amended) A method according to claim 23, wherein the mixing of gelatine, hyaluronic acid (HA) or a hyaluronate salt derivative thereof, and a solvent is performed by any of the following alternatives:
- a) mixing gelatine with hyaluronic acid (HA) or a hyaluronate salt derivative thereof and subsequently adding a solvent;
- b) mixing a solution of gelatine with a solution of hyaluronic acid (HA) or a hyaluronate salt derivative thereof;

- c) mixing gelatine with a solution of hyaluronic acid (HA) or a hyaluronate salt derivative thereof;
- d) mixing a solution of gelatine with hyaluronic acid (HA) or a hyaluronate salt derivative thereof.
- 30. (Withdrawn) The method according to any of claims 23 or 27, wherein said mixing is performed under mechanical influence.

31-35. (Canceled)

- 36. (Withdrawn / Currently amended) The method according to any of claims 23 or 27, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is provided in the form of a gel.
- 37. (Withdrawn / Previously presented) The method according to any of claims 24 or 27, wherein said drying is performed at a temperature from 20°C to 40°C.
- 38. (Withdrawn / Previously presented) The method according to any of claims 24 or 27, wherein said drying is conducted for 6 to 24 hours.
- 39. (Withdrawn) The method according to any of claims 24 or 27, wherein said drying is performed by freeze-drying.

40. (Canceled)

41. (Withdrawn) The method according to any of claims 23 or 27 wherein said mixing is performed by whipping, stirring, spinning, static mixing, motionless mixing or centrifugation.

42-47. (Canceled)

- 48. (Previously presented) The haemostatic composition according to claim 103, wherein said composition comprises at the most 85% (w/w) of said gelatin.
- 49. (Canceled)
- 50. (Previously presented) The haemostatic composition according to claim 103, wherein said composition comprises at the most 75% (w/w) of said gelatin.
- 51. (Previously presented) The haemostatic composition according to claim 103, wherein said composition comprises at the most 70% (w/w) of said gelatin.
- 52. (Previously presented) The haemostatic composition according to claim 103, wherein said composition comprises at the most 65% (w/w) of said gelatin.
- 53. (Previously presented) The haemostatic composition according to claim 103, wherein said composition comprises at the most 60% (w/w) of said gelatin.
- 54. (Currently amended) The haemostatic composition according to claim 103, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 15% (w/w).
- 55. (Canceled)
- 56. (Currently amended) The haemostatic composition according to claim 103, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 25% (w/w).
- 57. (Currently amended) The haemostatic composition according to claim 103, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 30% (w/w).

- 58. (Currently amended) The haemostatic composition according to claim 103, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 35% (w/w).
- 59. (Currently amended) The haemostatic composition according to claim 103, wherein said hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is incorporated into said composition to a final content of at least 40% (w/w).
- 60. (Canceled)
- 61. (Previously presented) The haemostatic composition according to claim 103, wherein the hyaluronic acid (HA) is physically cross-linked.
- 62. (Previously presented) The haemostatic composition according to claim 103, wherein the hyaluronic acid (HA) has a pH value in the range of from 5 to 9.
- 63-102. (Canceled)
- 103. (Currently amended) A sterile haemostatic composition comprising gelatin and hyaluronic acid (HA) or a hyaluronate salt derivative thereof, wherein said gelatin and hyaluronic acid (HA) or a hyaluronate salt derivative thereof, is stabilized with dry heat at 110-200°C, and wherein said haemostatic composition does not comprise a chemical cross-linking agent or residues thereof.
- 104. (Canceled)
- 105. (Currently amended) The haemostatic composition according to <u>claim 103</u> any of claims 101-104, wherein said composition is in the form of a sponge, powder or flakes.

- 106. (Previously presented) The haemostatic composition according to claim 105, wherein said composition is in the form of a haemostatic sponge and wherein said sponge absorbs less water than an absorbable gelatin sponge.
- 107. (Currently amended) The haemostatic composition according to <u>claim 103</u> any of claims 101 104, wherein said composition comprises at the most 80% (w/w) of said gelatin.
- 108. (Currently amended) The haemostatic composition according to <u>claim 103</u> any of claims 101-104, wherein said hyaluronic acid (HA) or a <u>hyaluronate</u> salt <u>derivative</u> thereof, is incorporated into said composition to a final content of at least 20% (w/w).
- 109. (Canceled).
- 110. (Previously presented) The haemostatic composition according to claim 103, wherein said dry heat treatment at 110-200°C is conducted for 15 minutes to 6 hours.
- 111. (Canceled)
- 112. (Canceled)
- 113. (Canceled)
- 114. (new) The haemostatic composition according to claim 103, wherein said hyaluronic acid (HA) or a salt thereof, is incorporated into said composition to a final content of at least 10% (w/w).